TScan Therapeutics, Inc. (NASDAQ:TCRX – Get Rating) – Stock analysts at Wedbush issued their Q2 2023 earnings per share estimates for shares of TScan Therapeutics in a note issued to investors on Wednesday, June 21st. Wedbush analyst D. Nierengarten expects that the company will post earnings per share of ($0.27) for the quarter. Wedbush currently has a “Outperform” rating and a $8.00 price target on the stock. The consensus estimate for TScan Therapeutics’ current full-year earnings is ($2.52) per share. Wedbush also issued estimates for TScan Therapeutics’ Q3 2023 earnings at ($0.25) EPS, Q4 2023 earnings at ($0.26) EPS, FY2023 earnings at ($1.25) EPS, Q1 2024 earnings at ($0.26) EPS, Q2 2024 earnings at ($0.26) EPS, Q3 2024 earnings at ($0.26) EPS, Q4 2024 earnings at ($0.24) EPS, FY2024 earnings at ($1.02) EPS, FY2025 earnings at ($0.96) EPS, FY2026 earnings at ($0.96) EPS and FY2027 earnings at ($0.71) EPS.
Separately, HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of TScan Therapeutics in a report on Thursday, March 9th.
TScan Therapeutics Trading Down 4.6 %
TScan Therapeutics (NASDAQ:TCRX – Get Rating) last released its earnings results on Wednesday, May 10th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by ($0.20). The business had revenue of $6.80 million for the quarter, compared to analysts’ expectations of $3.10 million. TScan Therapeutics had a negative net margin of 419.38% and a negative return on equity of 68.23%.
Insiders Place Their Bets
In other news, major shareholder Lynx1 Capital Management Lp sold 25,400 shares of TScan Therapeutics stock in a transaction on Wednesday, May 31st. The shares were sold at an average price of $2.52, for a total transaction of $64,008.00. Following the completion of the sale, the insider now directly owns 5,224,600 shares of the company’s stock, valued at approximately $13,165,992. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other news, Director Timothy J. Barberich acquired 37,880 shares of the company’s stock in a transaction dated Friday, June 2nd. The stock was acquired at an average cost of $2.63 per share, for a total transaction of $99,624.40. Following the acquisition, the director now directly owns 37,880 shares in the company, valued at approximately $99,624.40. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Lynx1 Capital Management Lp sold 25,400 shares of the stock in a transaction that occurred on Wednesday, May 31st. The shares were sold at an average price of $2.52, for a total transaction of $64,008.00. Following the completion of the sale, the insider now directly owns 5,224,600 shares of the company’s stock, valued at approximately $13,165,992. The disclosure for this sale can be found here. 8.27% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the business. State Street Corp increased its position in TScan Therapeutics by 79.1% during the first quarter. State Street Corp now owns 24,000 shares of the company’s stock worth $50,000 after buying an additional 10,600 shares during the last quarter. Simplify Asset Management Inc. bought a new position in TScan Therapeutics in the 1st quarter worth approximately $1,149,000. Millennium Management LLC acquired a new position in shares of TScan Therapeutics during the fourth quarter valued at $31,000. Alphabet Inc. acquired a new stake in shares of TScan Therapeutics during the third quarter worth $3,285,000. Finally, Vanguard Group Inc. raised its position in shares of TScan Therapeutics by 13.9% in the 3rd quarter. Vanguard Group Inc. now owns 257,416 shares of the company’s stock valued at $785,000 after acquiring an additional 31,352 shares during the period.
TScan Therapeutics Company Profile
TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 that is in Phase I of clinical trial for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-204 that is in Phase I for the treatment of solid tumors.
Featured Articles
- Get a free research report on TScan Therapeutics from StockNews.com
- MarketBeat Week in Review – 6/19 – 6/23
- CarMax Stock Flying On Earnings Beat, Return Of The Highs?
- Commercial Metals Company Shakes Off The Rust: Confirms Uptrend
- Smith & Wesson, A Timeless Value Play At Decade Lows
- Five stocks we like better than TScan Therapeutics
Receive News & Ratings for TScan Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TScan Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
